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Liver oxidative stressHyperhomocysteinemia (HHcy) is associated with cardiovascular disease, atherosclerosis and reactive oxygen
species generation. Thus, our aim was to investigate whether there was an association between HHcy, blood
pressure, autonomic control and liver oxidative stress. Male Wistar rats were divided into 2 groups and treated
for 8 weeks: one group (control, CO) received tap water, while the other group (methionine, ME) was given a
100 mg/kg of methionine in water by gavage. Two catheters were implanted into the femoral artery and vein
to record arterial pressure (AP) and heart rate (HR) and drug administration. Signals were recorded by a data ac-
quisition system. Baroreﬂex sensitivity was evaluated by HR responses to AP changes induced by vasoactive
drugs. HR variability and AP variability were performed by spectral analysis in time and frequency domains to
evaluate the contribution of the sympathetic and parasympathetic modulation. Lipid peroxidation and antioxi-
dant enzyme activities were evaluated bymeasuring superoxide dismutase, catalase and glutathione peroxidase
in liver homogenates. The ME group presented a signiﬁcant increase in systolic arterial pressure (118 ± 9 vs
135± 6mmHg), diastolic arterial pressure (81 ± 6 vs. 92± 4) and mean arterial pressure (95± 7 vs. 106±
6). In addition, pulse interval variability presented a signiﬁcant decrease (41%), while the low frequency compo-
nent of AP was signiﬁcantly increased (delta P=6.24mmHg2) in the ME group. We also found a positive asso-
ciation between lipid peroxidation and cardiac sympatheticmodulation, sympathetic and vagalmodulation ratio
and systolic pressure variability. Collectively, theseﬁndings showed that HHcy induced dysfunction of cardiovas-
cular autonomic system and liver oxidative stress.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Homocysteine (Hcy) is a sulfur amino acid that is derived from die-
tary methionine, which is synthesized during metabolic conversion of
methionine to cysteine in the liver (Medina et al., 2001; Selhub,
2002). Plasma Hcy levels may be altered by genetic and nutritional fac-
tors (Refsum et al., 1998).
Hyperhomocysteinemia (HHcy) is usually deﬁned by level of Hcy:
(N12 and b30 μmol/L) moderate, (N30 and b100 μmol/L) intermediate
and (100 μmol/L) severe (De Bree et al., 2002; Van Guldener et al.,ncias da Saúde de Porto Alegre,
0, Porto Alegre, RS, Brazil. Tel.:
ghts reserved.2003). HHcy occurs in about 5–7% of the world population (Seshadri
et al., 2002; Suematsu et al., 2007).
Moderate HHcy (12–30 μmol/L) is prevalent and an independent
risk factor for cardiovascular disease and atherosclerosis. The precise
underlyingmechanism thatwould account for the relationship between
Hcy and atherosclerosis remains unclear. However, studies using
genetic- and diet-induced animal models of HHcy show a direct causal
relationship between HHcy, endothelial dysfunction and accelerated
atherosclerosis (Lawrence de Koning et al., 2003).
Physiopathological features of HHcy are similar to some physiopath-
ological features found in sympathetic overactivity in the cardiovascular
system. Both are characterized by increased platelet aggregation, prolif-
eration of vascular smoothmuscle, accelerated atherosclerosis, left ven-
tricular hypertrophy and arterial hypertension (Bortolotto et al., 1999).
It is well documented in the literature that HHcy provokes an activation
of the sympathetic system, and this fact contributes to vascular and end-
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1999; Muntzel et al., 2006).
HHcy induced by methionine supplementation is also associated
with the liver. The increase of methionine might lead to liver oxida-
tive/nitrosative stress increment and Hcy itself has the ability to gener-
ate potent reactive oxygen species (ROS) when oxidized by highly
reactive sulfhydryl group (Yamada et al., 2012). Another mechanism is
the HHcy-induced endothelial injury throughout Hcy oxidation that
generates homocysteine, leading to the generation of superoxide and
hydrogen peroxide (Steed and Tyagi, 2011). In fact, in vitro studies or
experimental models have associated HHcy with oxidative stress
(Lubos et al., 2007; Mendes et al., 2010).
Establishing a solid association between HHcy, liver oxidative stress
and blood pressure variability is critical for development of new thera-
peutic strategies for hypertension.Wewould like to stress that no previ-
ous studyhas so far evaluated the effects ofmethionine supplementation
on cardiovascular autonomic systemandbaroreﬂex associatedwith liver
oxidative stress.
Therefore, the aimof this studywas to investigate the effects of HHcy
on blood pressure and sympathetic and parasympathetic functions and
the impact about some oxidative stress parameters in the liver.
2. Material and methods
2.1. Animals and experimental groups
Twelve male Wistar rats (250–300g) from the Federal University of
São Paulo, Brazil were housed in plastic cages (3 animals each), with ac-
cess to water and regular food ad libitum, and maintained under con-
trolled temperature (21 °C) and 12 h light/dark cycle. They were
divided in 2 groups and treated by a daily gavage: 1) control (CO) re-
ceiving water only and 2) methionine (ME) receiving methionine
(100mg/kg) diluted in water. After 8weeks, animals were killed by de-
capitation. All animal procedures were carried out in accordance with
the “Guide for the Care and Use of Laboratory Animals” (National Insti-
tutes of Health publication no. 85-23, revised 1985).
2.2. Determination of plasma Hcy concentration
Total Hcy concentration in plasma was measured by high-
performance liquid chromatography with ﬂuorescence detection
(de Oliveira et al., 2002).
2.3. Hemodynamic measurements
Oneday after the endof treatment, 2 catheters ﬁlledwith 0.06mL sa-
line were implanted into the femoral artery and vein (PE-10) of anes-
thetized rats (50 mg/kg ketamine and 10 mg/kg xylazine) for direct
measurements of AP and drug administration, respectively. Rats receiv-
ing food and water ad libitum were studied 1 day after catheter place-
ment; the rats were conscious and allowed to move freely in the cage
during the experiments. The arterial cannula was connected to a strain
gauge transducer 6 (P23Db, Gould-Statham), andblood pressure signals
were recorded over a 20-minute period by a microcomputer equipped
with an analog-to-digital converter board (using a Dataq Instruments
DI-720, 16-bit measurement resolution, 250 Hz sampling rate).
WINDAQ/PRO waveform recording software was used for the acquisi-
tion at 2000Hz per channel.
The recorded data were analyzed on a beat-to-beat basis to quantify
changes in mean (MAP), systolic (SAP) and diastolic arterial pressure
(DAP) and heart rate (HR). Increasing doses of phenylephrine (0.25 to
32μg/kg) and sodiumnitroprusside (0.05 to 1.6μg/kg)were given as se-
quential bolus injections (0.1mL) to produce blood pressure responses
ranging from 5 to 40mmHg. A 3 to 5-minute interval between doses
was necessary for blood pressure to return to its baseline. Peak increases
or decreases in MAP after phenylephrine or sodium nitroprussideinjection and the corresponding peak reﬂex changes in HRwere record-
ed for each dose of the drug. Baroreﬂex sensitivity (BRS) was evaluated
by a mean index through a relationship between changes in HR and in
MAP, allowing separate analysis of bradycardia and tachycardia re-
ﬂexes. Themean index was expressed as beats per minute per millime-
ter of mercury (Farah et al., 1999).
2.4. Blood pressure and pulse interval variability
Time-domain analysis consisted of calculating the mean pulse inter-
val (PI) and systolic arterial pressure (SAP), as well as their variability as
the standard deviation from their respective time series. In the
frequency-domain analysis, Fast Fourier Transforming (FFT) method
was used to evaluate SAP, PI and RR interval variability (SBPV and PIV,
respectively). The spectral bands for rats (very low frequency (VLF):
0.0–0.2 Hz; low frequency (LF): 0.2–0.75 Hz; high frequency (HF):
0.8–2.8 Hz) were deﬁned according to the literature (Grassi et al.,
1995; Hiratzka, 1996).
Spectral power for LF and HF bands was calculated by means of
power spectrum density integration within each frequency bandwidth.
The power density of each spectral component was calculated both in
absolute values and in normalized units. Power in LF and in HF for
pulse intervals was normalized by calculating the variance minus the
power in very low frequency (VLF) and was expressed in normalized
units. The sympathetic and vagal modulation ratio balance was deﬁned
by the LFnu/HFnu ratio.
The LF components of the PIV and LF components of the SBPV were
consideredmarkers of efferent sympathetic cardiac and vascularmodu-
lation, respectively, whereas the HF component of the PIV reﬂected
respiratory-driven vagal modulation to the sinoatrial node. For
frequency-domain analysis, the entire ten-minute time series of blood
pressure and pulse, or RR intervals, were evaluated under basal condi-
tions using non-parametric methods (FFT), described in detail above.
Beat-to-beat values of SBP and PI intervals were used to estimate the
cardiac BRS by spectral analysis, using the alpha index for the low-
frequency band (0.20–0.75 Hz). The alpha index analysis evaluates
short-term changes in the systolic arterial pressure and in the RR
interval.
The coherence between the PI and the SBP signal variability was
assessed by means of a cross-spectral analysis. The alpha index in the
LF bandwas calculated only when themagnitude of the squared coher-
ence between the PI and SBP signals exceeded 0.5 (range, 0–1). After co-
herence calculation, the alpha index was obtained from the square root
of the ratio between PI and SBP variability in the two major LF bands
(Soares et al., 2004; Moraes-Silva et al., 2013).
2.5. Tissue preparation
Livers were rapidly excised, weighed and homogenized (1.54mol/L
potassium chloride, phenylmethyl sulfonyl ﬂuoride 20 mmol/L) in
ULTRA-TURRAX (Fisher Scientiﬁc, Canada). The suspension was centri-
fuged at 6000 g for 10min at 0 °C to 4 °C to remove the nuclei and cell
debris. The supernatant was stored at−80 °C for biochemical analysis.
2.6. Determination of oxidative stress parameters
Catalase (CAT) activity was determined by following the decrease in
hydrogen peroxide (H2O2) absorbance at 240 nm. It was expressed as
nanomoles of H2O2 reduced per minute per milligram of protein
(Aebi, 1984). Superoxide dismutase (SOD) activity, expressed as units
permilligram of protein, was based on the inhibition of superoxide rad-
ical reaction with pyrogallol (Marklund, 1985). GSHPx activity was de-
termined by monitoring NADPH oxidation spectrophotometrically at
340 nm, and the results are reported as nmol/min/mg protein (Flohe
and Gunzler, 1984).
Table 2
Spectral parameters of pulse interval after methionine treatment.
PI CO (n=6) ME (n=6) P
PIV (ms2) 113±31 66.54±34 0.03
LFa (ms2) 2.93±1.41 8.30±6.01 0.08
HFa (ms2) 13±8.0 9.61±3.0 0.35
LFnu (%) 19±4 52±22 0.005
HFnu (%) 80±4 48±22 0.005
LF/HF ratio (ms2) 0.23±0.05 1.28±1 0.03
Data are reported as mean±SD. Results of pulse interval variability (PIV), and frequency
domains (LF: low frequency, HF: high frequency, LFnu: low frequency normalized, HFnu:
high frequency normalized).
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tiated chemiluminescence (CL) by scintillation counter in the out-of-
coincidence mode (LKB Rack Beta Liquid Scintillation Spectrometer
1215, LKB-Produkter AB, Sweden) (Gonzalez Flecha et al., 1991).
2.7. Protein determination
Protein was measured by the method of Lowry et al. (1951), using
bovine serum albumin as standard. The results were expressed in mg
of protein/mL.
2.8. Statistical analysis
The data are expressed as mean± SD. Student's t test was used to
compare groups and differences were considered signiﬁcant when
Pb0.05. Pearson correlation was used to study the association between
variables. Statistical analyses were performed using GraphPad InStat
3.02 for Windows (San Diego, California, USA) and Sigma Plot 12.0.
3. Results
3.1. Plasma Hcy concentration
As expected, Hcy concentration in plasma (mol/L) in the ME treated
rats (16.81 ± 2.39) was signiﬁcantly higher than CO (11.95 ± 3.16)
(PN0.05, n=4/group).
3.2. Hemodynamic and autonomic parameters
Tables 1, 2 and Fig. 1 show the cardiovascular and spectral measure-
ments. There was a signiﬁcant increase in SAP, DAP andMAP in animals
that received methionine supplementation (ME group). The treatment
induced an important reduction in both tachycardic response (TR) and
bradycardic response (BR).
PIV presented a signiﬁcant decrease in animals that received supple-
mentation (ME group). The LF of PIV and systolic arterial pressure vari-
ability was signiﬁcantly increased in the ME group. HF% presented a
signiﬁcant decrease in the ME group while the LF/HF was signiﬁcantly
increased in the ME group. In contrast, the BRS estimated by alpha
index was signiﬁcantly decreased in the ME group. On the other hand,
regarding to SAPV, we found a signiﬁcant increase in LF (3.1 ± 0.5 vs
9.34 ± 6) and a decrease in BRS (1.29 ± 0.5 vs 0.75± 0.2) in the ME
group as estimated by alpha index (Fig. 1).
3.3. Liver oxidative stress parameters
Changes in lipid peroxidation, GSHPx, CAT and SOD in liver samples
are reported in Table 3. Therewas a signiﬁcant increase (49 and 66%, re-
spectively) in lipid peroxidationmeasured by CL andGSHPx activities in
animals that received methionine supplementation (ME group). There
were no changes in CAT and SOD activities considering treatment.Table 1
Cardiovascular measurements in experimental groups: hemodynamic variables.
Parameters CO (n=6) ME (n=6) P
Hemodynamics
SAP (mmHg) 118± 9 135± 6 0.003
DAP (mmHg) 81± 6 92± 4 0.004
MAP (mmHg) 95± 7 106± 6 0.01
HR (bpm) 323± 17 343± 20 0.09
TR (bpm/mmHg) 2.5± 0.5 1.2± 0.4 0.0006
BR (bpm/mmHg) −2.0± 0.5 −1.3± 0.2 0.009
Data are reported as means ± SD. Results of systolic arterial pressure (SAP), diastolic
arterial pressure (DAP), mean arterial pressure (MAP), heart rate (HR), tachycardic
response (TR), bradycardic response (BR).3.4. Correlation analysis
Correlation analyses were carried out associating autonomic and
cardiac oxidative stress parameters. Regarding the arterial pressure,
there was a positive correlation between CL and cardiac sympathetic
modulation (LF %), (r=0.63 P≤0.03), and also between CL and sympa-
thetic and vagal modulation balance (r=0.79 P≤0.01). In addition, CL
also showed a positive and signiﬁcant association with sympathetic
modulation of blood pressure (LF of SAP) (r = 0.76 P ≤ 0.01) and
blood pressure total variance (SAPV) (r=0.78 P≤0.004).
4. Discussion
The main ﬁnding of the present study was that the ME supplemen-
tation promoted a moderate state of HHcy, which was accompanied
by an increase in SAP, DAP and MAP. This increase was also associated
with an increase in sympathetic modulation and a decrease in parasym-
pathetic modulation. In addition, there was a positive association be-
tween CL and cardiac sympathetic modulation, sympathetic and vagal
modulation ratio (LF/HF) and systolic pressure variability (SAPV). Col-
lectively, these results reinforce the hypotheses that the HHcy increased
blood pressure and liver oxidative stress.
As previously described by our group, the same protocol of ME sup-
plementation was able to signiﬁcantly increase the Hcy blood concen-
tration, promoting a moderate HHcy in rats (Mendes et al., 2010).
Moreover, our results are in agreement with an experimental study
which adopted the strategy of folate deﬁciency for inducing HHcy.
This study also showed a signiﬁcant increase in SAP, measured by te-
lemetry, associated with increased heart, kidney and liver oxidative
stress (Pravenec et al., 2013).
A possible mechanism, which may account for the association be-
tweenHHcy and increased arterial pressure, is the impairment of vascu-
lar endothelial function (He et al., 2010). It is well established that HHcy
provokes an increase in vascular thickness and elastin fragmentation
and a decrease in vessel wall elastic compliance (Steed and Tyagi,
2011). Combined, these ﬁndings may have contributed to the increase
in SAP, DAP andMAP in theME group found in our study that it is in ac-
cordance to the autonomic imbalance. In fact, in a previous study with
normotensive subjects,we have demonstrated that a 10mmHg increase
in themean arterial pressure also increased the LF component participa-
tion and the LF/HF ratio (Vargas et al., 2013).
In the present study HHcy also resulted in impaired BRS, an auto-
nomic reﬂex to buffer beat-to-beat ﬂuctuations in arterial blood pres-
sure (Thomas, 2011), followed by impaired autonomic balance,
probably due to an increase in sympathetic modulation. On the other
hand, our results did not corroborate an experimental study that
found an increase in BRS after 15days of DL-Hcy thiolactone treatment
(Resstel et al., 2008). The difference in the results may be probably due
to the time of treatment. In our study, rats underwent a longer exposure
to methionine, which may have resulted in impaired vascular function
and autonomic modulation, and consequently BRS.
The reduction in spontaneous BRS, seen by alpha index, accompa-
nied by an increase of LF component and heart rate variability and a
Fig. 1. A: Low frequency band of systolic arterial pressure. B: Systolic arterial pressure variability. C: Spontaneous baroreﬂex sensitivity evaluated by alpha index. Data are reported as
mean± SD.
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ly, these ﬁndings may conﬁrm that HHcy is associated with increased
cardiac and AP sympathetic participation (Ebesunun et al., 2008;
Resstel et al., 2008; Zivkovic et al., 2012) and a decrease in pulse interval
variability (Hiratzka, 1996).
In fact, it has been demonstrated that the decrease in LF component
may also be associated to BRS impairment (Robbe et al., 1987; FarahVde
et al., 2007). This is conﬁrmed by another study of our group, which
found an association between the abolishment of BRS and the reduction
in LF component of HR variability, resulting in a worse cardiac remodel-
ing (Mostarda et al., 2010). These results lend support to the hypothesis
that the efﬁcient functioning of the autonomic nervous system is depen-
dent on a balance between the sympathetic and parasympathetic ner-
vous system. Either an increase or a decrease in any of the autonomic
components may cause an impairment of the BRS due to a reduction
in the heart capacity to buffer arterial pressure alterations.
Consequences of the autonomic dysfunction associated with the
HHcy may include pro-atherogenic effects. Evidence has shown that
Hcy is not only related to atherogenic effects, but also to an increased
in coagulation (Gerdes et al., 2004). In addition, the atherogenicity of
Hcy might be associated with several mechanisms that include the
LDL oxidation and the in vitro and in vivo HDL decrease (Xiao et al.,
2011).
Moreover, studies have found an association between autonomic
modulation and oxidative stress, which may, at least in part, account
for the impairment of ANS modulation in the ME group found in our
study. An experimental study has shown that NADPH might activateTable 3
Liver oxidative damage and antioxidant enzyme activities after ME treatment.
Parameters CO (n=6) ME (n=6)
CL (cps/mg prot 103) 10.5± 2.1 15.6± 3.3*
CAT (pmol/mg prot) 162.7± 40.7 148.3± 54.3
SOD (U/mg prot) 7.8± 0.6 7.4± 0.3
GSHPx (nmol/min/mg prot) 30.3± 11.6 50.2± 12.8*
Data are reported as means ± SD. *P b 0.05 vs C. Results of chemiluminescence (CL),
catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSHPx).sympathetic nervous system and thus resulting in hypertension
(Hirooka et al., 2011). As already demonstrated by other authors HHcy
induces endothelial dysfunction through the generation of oxygen free
radical and decrease in NO bioavailability (Jin et al., 2007).
Regarding to this association, our results demonstrated signiﬁcant
correlations between CL and LF component of IP, sympathetic and
vagal balance and systolic arterial pressure variability, which partially
explain the impairment in ANS modulation to the heart and the conse-
quent decrease in BRS.
The liver is the central organ of methionine metabolism, and
of the turnover of total body GSH (Lauterburg et al., 1984). Our
results showed an increase in liver GSHPx activity measured by
spectrophotometry. Glutathione peroxidase-1, a selenocysteine-
containing antioxidant enzyme, might be a key target of Hcy's dele-
terious action (Lubos et al., 2007). One plausible explanation for the
increase of GSHPx is an increase of thiol ingestion due to methio-
nine, and a possible overexpression of GPx-1 to compensate the
effects of methionine supplementation induced HHcy moderate.
Furthermore, the liver oxidative stress results are in agreement
with Stefanello et al. (2009) and Fujita et al. (2012), which also
found a worsening in the oxidative stress markers after ME treat-
ment and Woo et al. (2006) who have demonstrated a signiﬁcant
increase of malondialdehyde levels in the liver after high-ME diet
for 4 weeks. This is probably explained by the increase of lipid
peroxidation that is associated with the decrease of antioxidant
enzymes and thiol content in the HHcy (Ventura et al., 2000;
Racek et al., 2005; Devi et al., 2006).
CAT and SOD activities were not different between control and ME
groups. Another study using folate depletion as experimental model of
HHcy found no difference between CAT activity and decrease in Cu–Zn
SOD during 4 weeks of experimental protocol (Huang et al., 2001).
The results of CAT and SOD may be associated with adaptation of
antioxidant enzymatic system.
Therefore, these ﬁndings provide evidence that moderate HHcy
induced by ME impairs the cardiovascular autonomic control
which results in increased arterial pressure and it is associated
with liver oxidative stress. Collectively, our results reinforce the
importance of adopting healthy eating habits, specially increasing
the antioxidant food consumption, in order to have a longer and
healthy life.
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